Skip to main content
Premium Trial:

Request an Annual Quote

CHA Selects Cepheid as Vendor of Choice for Molecular MRSA Tests

NEW YORK (GenomeWeb News) – Cepheid said yesterday that the Connecticut Hospital Association Shared Services Program for molecular surveillance of methicillin-resistant Staphylococcus aureus has selected Cepheid as its vendor of choice for the tests.
The CHA, which has 164 acute-care member hospitals, will exclusively market Cepheid’s GeneXpert Systems and Xpert MRSA test to its hospitals at pre-negotiated prices.
The program extends beyond Connecticut with member hospitals in eight other states including Massachusetts, Maine, Rhode Island, New Hampshire, Vermont, Illinois, Wyoming, and Iowa. Among these states, Illinois mandates surveillance of MRSA in hospitals, and legislation has been introduced in four of the other states for measures to prevent and control healthcare-associated infections, Cepheid said.
The CHA program includes hospitals with as few as 50 beds and as many as 800 beds, noted Rob Koska, Cepheid’s senior VP of worldwide commercial operations, in a statement.

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.